Brazil's industry leaders promise new impetus
This article was originally published in Clinica
A new stage in the evolution of Brazil's medical technology arena is afoot, with the appointment of new presidents at industry associations ABIMO and SINAEMO (which represents the sector's healthcare-political interests). Their key aims are to promote better access to medtech, in line with the federal government's healthcare priorities, and to work towards meeting up to 95% of the US$3.2bn market's needs from domestic manufacturing.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.